<DOC>
	<DOCNO>NCT01439360</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , immunogenicity safety GSK Biologicals ' influenza candidate vaccine GSK2321138A compare non-influenza vaccine comparators child 6 35 month age . Recruitment encompass least 4 independent cohort : first cohort Northern Hemisphere ( 2011-2012 ) , second cohort subtropical country ( 2012 ) , third cohort Northern Hemisphere ( 2012-2013 ) fourth cohort additional independent cohort possibly NH country ( end 2013 ) subtropical country ( begin 2014 ) .</brief_summary>
	<brief_title>An Efficacy Study GlaxoSmithKline ( GSK ) Biologicals ' Candidate Influenza Vaccine GSK2321138A Children</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Subjects investigator believe parents/Legally Acceptable Representative ( LARs ) comply requirement protocol . A male female , include , 6 35 month age time first vaccination ; child eligible regardless history influenza vaccination . Written inform consent obtain parent ( ) /LAR ( ) subject . Subjects stable health determine medical history clinical examination enter study . Participation previous FLUDQIV004 study ( 115345 ) cohort . Child care . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . Prior receipt influenza vaccine within 6 month precede first dose study vaccine , plan use vaccine study period . Children underlie illness risk complication influenza yearly ( seasonal ) influenza vaccination recommend respective country . Any confirm suspected immunosuppressive immunodeficient condition ( include HIV ) , base medical history physical examination . Chronic administration immunosuppressant immune modify drug within six month prior first vaccine dose . Inhaled topical steroid allow . Administration immunoglobulins and/ blood product within 3 month precede first dose study vaccine plan administration study period . Any known suspected allergy constituent influenza vaccine , noninfluenza vaccine comparators latex ; history anaphylactictype reaction consumption egg ; history severe adverse reaction previous vaccination . Any contraindication intramuscular injection . Acute disease and/or fever time enrolment . Any condition , opinion Investigator , prevents subject participate study . Additional criterion child â‰¥ 12 month age : Prior receipt license varicella vaccine* license hepatitis A vaccine plan use vaccine study period . Other routine register childhood vaccination permit . * For country varicella vaccine administer 2dose schedule , prior receipt single dose varicella vaccine allow administer least 2 week first study vaccination . Any history hepatitis A varicella disease . Additional criterion child 6 11 month age country without universal mass vaccination recommendation pneumococcal vaccine : Prior receipt pneumococcal conjugate vaccine plan use vaccine study period . Other routine register childhood vaccination permit .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>35 Months</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Vaccine</keyword>
	<keyword>Seasonal Flu</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Children</keyword>
</DOC>